JP2023503611A - 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法 - Google Patents

造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法 Download PDF

Info

Publication number
JP2023503611A
JP2023503611A JP2022530672A JP2022530672A JP2023503611A JP 2023503611 A JP2023503611 A JP 2023503611A JP 2022530672 A JP2022530672 A JP 2022530672A JP 2022530672 A JP2022530672 A JP 2022530672A JP 2023503611 A JP2023503611 A JP 2023503611A
Authority
JP
Japan
Prior art keywords
masp
subject
antibody
inhibitory antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022530672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503611A5 (https=
JPWO2021108447A5 (https=
Inventor
グレゴリー エイ． デモプロス
トーマス エイ． ダドラー
Original Assignee
オメロス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オメロス コーポレーション filed Critical オメロス コーポレーション
Publication of JP2023503611A publication Critical patent/JP2023503611A/ja
Publication of JP2023503611A5 publication Critical patent/JP2023503611A5/ja
Publication of JPWO2021108447A5 publication Critical patent/JPWO2021108447A5/ja
Priority to JP2026000091A priority Critical patent/JP2026062897A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
JP2022530672A 2019-11-26 2020-11-24 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法 Pending JP2023503611A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026000091A JP2026062897A (ja) 2019-11-26 2026-01-05 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940720P 2019-11-26 2019-11-26
US201962940735P 2019-11-26 2019-11-26
US62/940,720 2019-11-26
US62/940,735 2019-11-26
PCT/US2020/062082 WO2021108447A1 (en) 2019-11-26 2020-11-24 Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026000091A Division JP2026062897A (ja) 2019-11-26 2026-01-05 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法

Publications (3)

Publication Number Publication Date
JP2023503611A true JP2023503611A (ja) 2023-01-31
JP2023503611A5 JP2023503611A5 (https=) 2023-07-27
JPWO2021108447A5 JPWO2021108447A5 (https=) 2023-07-27

Family

ID=76130747

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530672A Pending JP2023503611A (ja) 2019-11-26 2020-11-24 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法
JP2026000091A Pending JP2026062897A (ja) 2019-11-26 2026-01-05 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026000091A Pending JP2026062897A (ja) 2019-11-26 2026-01-05 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法

Country Status (13)

Country Link
US (2) US20220064330A1 (https=)
EP (1) EP4065165A4 (https=)
JP (2) JP2023503611A (https=)
KR (1) KR20220104201A (https=)
CN (1) CN115335077A (https=)
AU (1) AU2020391175A1 (https=)
BR (1) BR112022010078A2 (https=)
CA (1) CA3159152A1 (https=)
CL (4) CL2022001355A1 (https=)
IL (1) IL293363A (https=)
JO (1) JOP20220113A1 (https=)
MX (1) MX2022006334A (https=)
WO (1) WO2021108447A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023108028A2 (en) 2021-12-10 2023-06-15 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533592A (ja) * 2015-11-09 2018-11-15 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
WO2019036460A1 (en) * 2017-08-15 2019-02-21 Omeros Corporation METHODS OF TREATING AND / OR PREVENTING HOST GRAFT DISORDER AND / OR DIFFUSE ALVEOLAR HEMORRHAGE AND / OR VENO-OCCLUSIVE DISEASE ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2704743B1 (en) * 2011-05-04 2020-03-11 Omeros Corporation Compositions for inhibiting masp-2 dependent complement acitivation
US10736960B2 (en) * 2016-01-05 2020-08-11 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
RU2018145364A (ru) * 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
EP3526249A4 (en) * 2016-10-17 2020-07-01 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INJURY ASSOCIATED WITH A GRAFT
CA3055781A1 (en) * 2017-03-14 2018-09-20 Bioverativ Usa Inc. Methods for treating complement-mediated diseases and disorders
EP3717004A4 (en) * 2017-12-01 2021-12-01 Children's Hospital Medical Center COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533592A (ja) * 2015-11-09 2018-11-15 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
WO2019036460A1 (en) * 2017-08-15 2019-02-21 Omeros Corporation METHODS OF TREATING AND / OR PREVENTING HOST GRAFT DISORDER AND / OR DIFFUSE ALVEOLAR HEMORRHAGE AND / OR VENO-OCCLUSIVE DISEASE ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 14, JPN6025027076, 2008, pages 23 - 32, ISSN: 0005784427 *
BLOOD, vol. 112, JPN6025027073, 2008, pages 3073 - 3081, ISSN: 0005784424 *
BONE MARROW TRANSPLANTATION, vol. 53, JPN6025027075, 2018, pages 515 - 518, ISSN: 0005784426 *
HEMATOLOGY, vol. 10(6), JPN6025027074, 2005, pages 469 - 481, ISSN: 0005784425 *

Also Published As

Publication number Publication date
US20240218080A1 (en) 2024-07-04
US20220064330A1 (en) 2022-03-03
CL2024001421A1 (es) 2024-08-23
EP4065165A4 (en) 2024-10-16
KR20220104201A (ko) 2022-07-26
MX2022006334A (es) 2022-06-22
IL293363A (en) 2022-07-01
CL2024001420A1 (es) 2024-08-23
AU2020391175A1 (en) 2022-07-07
CA3159152A1 (en) 2021-06-03
JOP20220113A1 (ar) 2023-01-30
CN115335077A (zh) 2022-11-11
WO2021108447A1 (en) 2021-06-03
CL2022001355A1 (es) 2023-05-19
BR112022010078A2 (pt) 2022-12-13
EP4065165A1 (en) 2022-10-05
CL2024001422A1 (es) 2024-08-23
JP2026062897A (ja) 2026-04-10

Similar Documents

Publication Publication Date Title
JP7397037B2 (ja) Ｍａｓｐ－２依存性補体活性化に関連した状態を治療するための方法
JP7629300B2 (ja) Ｍａｓｐ－２依存性補体活性化に関連した状態を治療するための方法
JP2023123627A (ja) 造血幹細胞移植に関連する移植片対宿主病および／またはびまん性肺胞出血および／または静脈閉塞症を治療および／または予防するための方法
JP2026062897A (ja) 造血幹細胞移植に関連する特発性肺炎症候群（ｉｐｓ）および／または毛細血管漏出症候群（ｃｌｓ）および／または生着症候群（ｅｓ）および／または体液過剰（ｆｏ）を治療および／または予防するための方法
HK40114300A (zh) 用於治疗和/或预防弥漫性肺泡出血的方法
HK40116756A (zh) 用於治疗和/或预防静脉闭塞性病的方法
HK40106322A (zh) 用於治疗与masp-2依赖性补体活化相关的病况的方法
RU2830289C2 (ru) Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
EA046178B1 (ru) Способы лечения и/или предотвращения реакции трансплантат против хозяина и/или диффузного альвеолярного кровотечения, и/или веноокклюзионной болезни, связанных с трансплантатом гемопоэтических стволовых клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260129